Fig. 2: Comparison of survival between patients with ≥15% BM RS and those with <15% BM RS in MDS/MPN-SF3B1-T patients.

BM bone marrow, RS ring sideroblasts, MDS/MPN-SF3B1-T myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis.